MoonLake CFO Matthias Bodenstedt Sells Shares

Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, sold 15,082 shares of the company on June 17, 2026. The shares were sold at an average price of $19.68, totaling approximately $296,813.76. This transaction was part of a planned sale.

MoonLake Immunotherapeutics Stock Snapshot

Shares of NasdaqCM:MLTX traded near $19.19. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The stock has experienced significant fluctuations, with a 52-week low of $5.95 and a high of $62.75. Its 50-day moving average is $17.88, while the 200-day moving average is $19.01. The company's current ratio is 8.60, and its quick ratio is 7.89, indicating strong liquidity. The debt-to-equity ratio stands at 39.68.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing treatments for inflammatory skin and joint diseases. The company's leading product, Sonelokimab, is a novel therapy targeting IL-17A and IL-17F for conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.

Bottom Line

This insider sale by MoonLake's CFO, Matthias Bodenstedt, is part of a planned transaction. Investors often watch insider transactions for signals about company prospects, but it's important to note that such sales can occur for many reasons unrelated to the business outlook. MoonLake's stock has shown volatility, and while the forward P/E ratio isn’t meaningful due to current losses, analysts maintain a 'buy' recommendation.